Wenfeng He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenfeng He has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
He Chen
Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
4 shared publications- Wengen Zhu
Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China
4 shared publications Yonghui Fu
Department of Psychiatry, Jiangxi Mental Hospital, Nanchang, China
3 shared publicationsLan Yan
Department of Psychiatry, Jiangxi Mental Hospital, Nanchang, China
2 shared publications- Linjuan Guo
Department of Cardiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China
2 shared publications Wanlei Sun
Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University, Jiangxi, China
2 shared publications
Latest Publications
- 4 December 2025
- Published by Elsevier in Metabolism
- Vol. 176, 156460
Aging and metabolism in HFpEF: Pathophysiology and therapeutic implications
- 4 December 2025
- Published by Elsevier in Metabolism
- Vol. 176, 156460
Aging and metabolism in HFpEF: Pathophysiology and therapeutic implications
- 2 June 2025
- Published by Springer Nature in Journal of Cluster Science
- Vol. 36 (4) , 1-13
Application of Liposome-Based Drug Delivery Systems in Tumor Treatment
- 2 June 2025
- Published by Springer Nature in Journal of Cluster Science
- Vol. 36 (4) , 1-13
Application of Liposome-Based Drug Delivery Systems in Tumor Treatment
- Open Access
- 30 April 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-17
The role of protein lactylation in brain health and disease: current advances and future directions
Lactate, the end product of glycolysis, plays a crucial role in cellular signaling and metabolism. The discovery of lactylation, a novel post-translational modification, has uncovered the role of lactate in regulating diseases, especially in the brain. Lactylation connects genetic encoding with protein function, thereby influencing key biological processes. Increasing evidence supports lactate-mediated lactylation as a critical modulator in neurological disorders. This review offers an overview of lactate metabolism and lactylation, highlighting recent advances in understanding the regulatory enzymes of lactylation and their role in the central nervous system. We investigate the impact of lactylation on brain dysfunctions, including neurodegenerative diseases, cerebrovascular disorders, neuroinflammation, brain tumors, and psychiatric conditions. Moreover, we highlight the therapeutic potential of targeting lactylation in treating brain disorders and outline key research gaps and future directions needed to advance this promising field.
- 30 April 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-17
Open AccessThe role of protein lactylation in brain health and disease: current advances and future directions
Lactate, the end product of glycolysis, plays a crucial role in cellular signaling and metabolism. The discovery of lactylation, a novel post-translational modification, has uncovered the role of lactate in regulating diseases, especially in the brain. Lactylation connects genetic encoding with protein function, thereby influencing key biological processes. Increasing evidence supports lactate-mediated lactylation as a critical modulator in neurological disorders. This review offers an overview of lactate metabolism and lactylation, highlighting recent advances in understanding the regulatory enzymes of lactylation and their role in the central nervous system. We investigate the impact of lactylation on brain dysfunctions, including neurodegenerative diseases, cerebrovascular disorders, neuroinflammation, brain tumors, and psychiatric conditions. Moreover, we highlight the therapeutic potential of targeting lactylation in treating brain disorders and outline key research gaps and future directions needed to advance this promising field.
- Open Access
- 17 April 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10
Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation
Atrial fibrillation (AF) is commonly prevalent in patients with hypertrophic cardiomyopathy (HCM). However, whether the prevalence and incidence of AF are different between genotype-positive vs. genotype-negative patients with HCM remains controversial. Recent evidence has indicated that AF is often the first presentation of genetic HCM patients in the absence of a cardiomyopathy phenotype, implying the importance of genetic testing in this population with early-onset AF. However, the association of the identified sarcomere gene variants with HCM occurrence in the future remains unclear. How the identification of these cardiomyopathy gene variants should influence the use of anticoagulation therapy for a patient with early-onset AF is still undefined. In this review, we sought to assess the genetic variants, pathophysiological pathways, and oral anticoagulation in patients with HCM and AF.
- 17 April 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10
Open AccessGenetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation
Atrial fibrillation (AF) is commonly prevalent in patients with hypertrophic cardiomyopathy (HCM). However, whether the prevalence and incidence of AF are different between genotype-positive vs. genotype-negative patients with HCM remains controversial. Recent evidence has indicated that AF is often the first presentation of genetic HCM patients in the absence of a cardiomyopathy phenotype, implying the importance of genetic testing in this population with early-onset AF. However, the association of the identified sarcomere gene variants with HCM occurrence in the future remains unclear. How the identification of these cardiomyopathy gene variants should influence the use of anticoagulation therapy for a patient with early-onset AF is still undefined. In this review, we sought to assess the genetic variants, pathophysiological pathways, and oral anticoagulation in patients with HCM and AF.
- 11 May 2022
- Published by Elsevier in International Journal of Cardiology
- Vol. 361, 40-46
Association of body mass index and prognosis in patients with HFpEF: A dose-response meta-analysis
- 11 May 2022
- Published by Elsevier in International Journal of Cardiology
- Vol. 361, 40-46
Association of body mass index and prognosis in patients with HFpEF: A dose-response meta-analysis
- 1 October 2020
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 20 (5) , 507-508
Author's Reply to Vaz et al.: "Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease"
- 1 October 2020
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 20 (5) , 507-508
Author's Reply to Vaz et al.: "Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease"
- Open Access
- 1 April 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (16) , e19615
Relationship between psychological factors and atrial fibrillation
Background: Although several studies have investigated the role of psychological factors in atrial fibrillation (AF), the results are still under debate. Therefore, we performed a meta-analysis to examine the relationship between psychological factors and the risk of incident AF. Methods: We systematically searched the PubMed and EMBASE databases from inception to December 2019 to identify eligible studies. The hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled by using a random-effects model. Results: A total of 11 cohort studies were included in this meta-analysis. There were 5, 2, 4, and 5 studies examining the association of anxiety, anger, depression, and psychological stress with AF, respectively. In the pooled analysis by a random-effects model, anxiety (HR = 1.10, 95%CI 0.97–1.24; P = .14), anger (HR = 1.08, 95%CI 0.95–1.23; P = .21), depression (HR = 1.15, 95%CI 0.98–1.35; P = .08), and work stress (HR = 1.14, 95%CI 0.98–1.34; P = .09) were not associated with the risk of AF. These results were not changed when we re-performed the analysis using a fixed-effects model. Conclusions: Based on current evidence, no associations were observed for anger, anxiety, and work stress with the risk of AF.
- 1 April 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (16) , e19615
Open AccessRelationship between psychological factors and atrial fibrillation
Background: Although several studies have investigated the role of psychological factors in atrial fibrillation (AF), the results are still under debate. Therefore, we performed a meta-analysis to examine the relationship between psychological factors and the risk of incident AF. Methods: We systematically searched the PubMed and EMBASE databases from inception to December 2019 to identify eligible studies. The hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled by using a random-effects model. Results: A total of 11 cohort studies were included in this meta-analysis. There were 5, 2, 4, and 5 studies examining the association of anxiety, anger, depression, and psychological stress with AF, respectively. In the pooled analysis by a random-effects model, anxiety (HR = 1.10, 95%CI 0.97–1.24; P = .14), anger (HR = 1.08, 95%CI 0.95–1.23; P = .21), depression (HR = 1.15, 95%CI 0.98–1.35; P = .08), and work stress (HR = 1.14, 95%CI 0.98–1.34; P = .09) were not associated with the risk of AF. These results were not changed when we re-performed the analysis using a fixed-effects model. Conclusions: Based on current evidence, no associations were observed for anger, anxiety, and work stress with the risk of AF.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Bioengineered
- Vol. 11 (1) , 872-882
ELFN1-AS1 accelerates cell proliferation, invasion and migration via regulating miR-497-3p/CLDN4 axis in ovarian cancer
Previous studies indicated that long non-coding RNAs (LncRNAs) were involved in the progression of multiple cancers including ovarian cancer (OV). LncRNA ELFN1-AS1 functioned as an oncogene in many cancers, but its potential roles in OV were largely unclear. In the current study, we were aimed at clarifying the biological roles and molecular mechanisms of ELFN1-AS1 in OV. We found that ELFN1-AS1 was significantly upregulated in OV tissues and cell lines. High expression of ELFN1-AS1 was associated with poor prognosis in OV patients. Knockdown of ELFN1-AS1 inhibited the proliferation, migration and invasion of SKOV3 cell lines and repressed tumor growth in xenografted ovarian models. Mechanistically, ELFN1-AS1 promoted the proliferation, migration and invasion of SKOV3 cells by sponging miR-497-3p. Additionally, CLDN4 was verified to be the target of miR-497-3p. Rescue experiments revealed that miR-497-3p inhibition could partly reverse the inhibitory effect of ELFN1-AS1 silencing on proliferation, migration and invasion of SKOV3 cell lines. Taken together, our findings indicated that ELFN1-AS1 acted as an oncogene in ovarian cancer through regulating the expression of CLDN4 by directly interacting with miR-497-3p. The results suggested that ELFN1-AS1 might act as a promising therapeutic target for OV. Graphical abstract
- 1 January 2020
- Published by Taylor & Francis in Bioengineered
- Vol. 11 (1) , 872-882
Open AccessELFN1-AS1 accelerates cell proliferation, invasion and migration via regulating miR-497-3p/CLDN4 axis in ovarian cancer
Previous studies indicated that long non-coding RNAs (LncRNAs) were involved in the progression of multiple cancers including ovarian cancer (OV). LncRNA ELFN1-AS1 functioned as an oncogene in many cancers, but its potential roles in OV were largely unclear. In the current study, we were aimed at clarifying the biological roles and molecular mechanisms of ELFN1-AS1 in OV. We found that ELFN1-AS1 was significantly upregulated in OV tissues and cell lines. High expression of ELFN1-AS1 was associated with poor prognosis in OV patients. Knockdown of ELFN1-AS1 inhibited the proliferation, migration and invasion of SKOV3 cell lines and repressed tumor growth in xenografted ovarian models. Mechanistically, ELFN1-AS1 promoted the proliferation, migration and invasion of SKOV3 cells by sponging miR-497-3p. Additionally, CLDN4 was verified to be the target of miR-497-3p. Rescue experiments revealed that miR-497-3p inhibition could partly reverse the inhibitory effect of ELFN1-AS1 silencing on proliferation, migration and invasion of SKOV3 cell lines. Taken together, our findings indicated that ELFN1-AS1 acted as an oncogene in ovarian cancer through regulating the expression of CLDN4 by directly interacting with miR-497-3p. The results suggested that ELFN1-AS1 might act as a promising therapeutic target for OV. Graphical abstract
- 4 September 2019
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 20 (2) , 139-147
Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review
The effect of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and liver disease remains largely unresolved. Therefore, we performed a meta-analysis to compare the efficacy and safety of NOACs with warfarin in this population.
- 4 September 2019
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 20 (2) , 139-147
Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review
The effect of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and liver disease remains largely unresolved. Therefore, we performed a meta-analysis to compare the efficacy and safety of NOACs with warfarin in this population.